Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Several other research firms also recently weighed in on IONS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, October 15th. The Goldman Sachs Group decreased their price objective on Ionis Pharmaceuticals from $58.00 to $41.00 and set a “neutral” rating for the company in a report on Tuesday, November 10th. Citigroup restated a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, October 21st. Needham & Company LLC dropped their price objective on shares of Ionis Pharmaceuticals from $86.00 to $54.00 and set a “buy” rating on the stock in a report on Monday, November 9th. Finally, TD Cowen dropped their price objective on shares of Ionis Pharmaceuticals from $84.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, November 10th. Nineteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $75.71.

Get Our Latest Stock Analysis on Ionis Pharmaceuticals

Ionis Pharmaceuticals Price Performance

Ionis Pharmaceuticals stock opened at $28.01 on Friday. The business’s 50 day simple moving average is $43.05 and its 200 day simple moving average is $64.30. Ionis Pharmaceuticals has a 12 month low of $27.25 and a 12 month high of $86.74. The company has a market cap of $4.66 billion, a price-to-earnings ratio of -8.44 and a beta of 0.43. The company has a current ratio of 5.43, a quick ratio of 7.73 and a debt-to-equity ratio of 3.42.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.57. The business had revenue of $242.72 million during the quarter, compared to the consensus estimate of $178.17 million. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The business’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period last year, the business posted ($0.80) earnings per share. Sell-side analysts forecast that Ionis Pharmaceuticals will post -3.57 EPS for the current year.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Shannon Devers sold 1,357 shares of the stock in a transaction on Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the sale, the executive vice president owned 17,811 shares in the company, valued at $775,490.94. This represents a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Hayden bought 5,000 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were bought at an average price of $29.64 per share, for a total transaction of $148,200.00. Following the transaction, the director owned 27,000 shares of the company’s stock, valued at approximately $800,280. This represents a 22.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 1.81% of the company’s stock.

Institutional Trading of Ionis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Worldquant Millennium Advisors LLC increased its position in shares of Ionis Pharmaceuticals by 48.2% during the third quarter. Worldquant Millennium Advisors LLC now owns 72,585 shares of the company’s stock valued at $3,241,000 after buying an additional 23,609 shares during the period. Great Point Partners LLC purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter worth about $18,753,000. Entropy Technologies LP lifted its holdings in shares of Ionis Pharmaceuticals by 36.6% in the third quarter. Entropy Technologies LP now owns 50,303 shares of the company’s stock worth $2,246,000 after buying an additional 13,488 shares in the last quarter. Jump Financial LLC lifted its holdings in shares of Ionis Pharmaceuticals by 54.0% in the third quarter. Jump Financial LLC now owns 471,682 shares of the company’s stock worth $21,061,000 after buying an additional 165,352 shares in the last quarter. Finally, FORA Capital LLC boosted its position in shares of Ionis Pharmaceuticals by 308.2% in the third quarter. FORA Capital LLC now owns 56,460 shares of the company’s stock valued at $2,520,000 after acquiring an additional 42,627 shares during the period. 93.86% of the stock is currently owned by institutional investors.

Ionis Pharmaceuticals Company Profile

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

Further Reading

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.